Addex Therapeutics Ltd
ADXN
$7.90
$0.202.60%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -93.83% | -93.19% | -87.35% | -74.36% | -71.75% |
| Total Other Revenue | 1,898.65% | 3,189.74% | 1,550.98% | 44.68% | -31.48% |
| Total Revenue | -70.70% | -79.60% | -81.84% | -74.03% | -71.54% |
| Cost of Revenue | -22.89% | -44.28% | -35.31% | -27.03% | -70.50% |
| Gross Profit | -49.13% | -31.96% | -407.91% | -207.09% | 68.74% |
| SG&A Expenses | -23.44% | -29.33% | -27.86% | -11.99% | -23.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.29% | -33.90% | -30.04% | -16.62% | -46.08% |
| Operating Income | 14.51% | 21.82% | 3.95% | -24.38% | 35.36% |
| Income Before Tax | -40.28% | -67.05% | -96.64% | -99.11% | 6.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.28% | -67.05% | -96.64% | -99.11% | 6.21% |
| Earnings from Discontinued Operations | -98.86% | -98.61% | 267.42% | 246.54% | 262.05% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -226.24% | -255.09% | 174.52% | 164.32% | 146.34% |
| EBIT | 14.51% | 21.82% | 3.95% | -24.38% | 35.36% |
| EBITDA | 10.42% | 21.51% | 10.71% | -16.35% | 38.34% |
| EPS Basic | -232.08% | -314.85% | 162.83% | 148.12% | 128.28% |
| Normalized Basic EPS | -31.09% | -53.06% | -66.94% | -54.59% | 40.38% |
| EPS Diluted | -232.08% | -321.56% | 161.20% | 146.91% | 127.67% |
| Normalized Diluted EPS | -31.09% | -53.06% | -66.94% | -54.59% | 40.38% |
| Average Basic Shares Outstanding | 7.73% | 10.03% | 17.99% | 32.13% | 42.11% |
| Average Diluted Shares Outstanding | 7.73% | 10.03% | 17.99% | 32.13% | 42.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |